Fund Overview - Sofinnova Partners has closed its latest fund, Sofinnova Capital XI, at €650 million ($750 million), exceeding its initial target [1] - The fund will focus on early-stage healthcare companies in the US and Europe, particularly in medical technology and biopharmaceuticals [1] Investment Strategy - The fund will leverage the expertise of partners with backgrounds in medical, business, and scientific fields [2][6] - It will participate in both follow-on and initial funding rounds, maintaining a focus on early-stage biotech and medtech ventures [2] Investor Commitment - The fund has secured commitments from a global network of institutional investors, including foundations, corporates, family offices, insurance companies, sovereign wealth funds, and pharmaceutical companies [3] - Investors are from Europe, Asia, North America, and the Middle East, with a mix of returning and new limited partners, indicating strong interest in Sofinnova's strategy [3] Management Insights - Antoine Papiernik, managing partner and chairman, emphasized that this fundraising is a pivotal moment for Sofinnova, allowing for increased investment in early-stage opportunities [4] - The firm aims to support visionary entrepreneurs and advance breakthroughs in science and medicine, reflecting confidence in their investment model [5] Current Activities - Sofinnova Capital XI is actively deploying capital and has already invested in several portfolio companies [5]

Lagos-based Ventures Platform, one of Africa’s most active early-stage investors, has raised $64 million so far for its second fund, targeting a final close of $75 million, founding partner Kola Aina tells TechCrunch. Among the investors is the Nigerian government, through its Investment in Digital and Creative Enterprises (iDICE) program, which marks the first time this government has invested in a VC fund. That’s significant, since Nigeria’s burgeoning startup community is home to the largest number of ...

Core Insights - The company, Octopus Future Generations VCT plc, focuses on investing in businesses that address significant societal challenges, providing investors with opportunities to participate in the growth of purpose-driven companies [1][2]. Financial Performance - The Net Asset Value (NAV) per share as of 30 June 2025 was 88.4p, reflecting a decrease of 0.4p per share (-0.5%) from 31 December 2024 [4][11]. - The company invested £4.5 million into five new and follow-on opportunities during the six-month period [5]. - The total net assets of the company stood at £52.6 million as of 30 June 2025 [11]. Fundraising Activities - An initial offer to raise up to £5 million was launched on 3 February 2025 and successfully closed on 1 April 2025 [6]. Dividend Declaration - A special dividend of 5.6p per share was declared on 22 August 2025, marking the company's first dividend payment [8][65]. Investment Strategy - The company aims to invest in businesses aligned with three key themes: revitalising healthcare, empowering people, and building a sustainable planet [7][16]. - As of 30 June 2025, the portfolio comprised 37 investments, with the following distribution: 19 in revitalising healthcare, 11 in empowering people, and 7 in building a sustainable planet [16]. Portfolio Performance - The NAV decline was attributed to downward valuation movements across 13 companies, which collectively decreased in value by £3.1 million [25]. - Conversely, 13 companies in the portfolio saw a collective increase in value of £3.2 million, indicating potential for growth despite economic challenges [26]. Compliance and Qualification - The company met the requirement for 80% of its funds to be invested in VCT-qualifying holdings by 30 June 2025, with 100% of the portfolio qualifying under HMRC rules [10][31]. Management and Team Changes - The company has committed to enhancing team resources to improve focus on driving returns and realisations from the existing portfolio [13].